Literature DB >> 7729639

Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury.

H S Debinski1, C S Lee, J A Danks, P I Mackenzie, P V Desmond.   

Abstract

BACKGROUND/AIMS: Pharmacokinetic studies in patients with cirrhosis have shown a decreased clearance of drugs metabolized by cytochrome P450, whereas drugs metabolized by glucuronidation frequently have a normal elimination. The mechanism for the apparent preservation of glucuronidation has not been elucidated. The aim of this study was to examine the expression of uridine 5'-diphosphate-glucuronosyltransferase (UGT) in human liver injuries.
METHODS: UGT was measured by immunohistochemistry using a UGT polyclonal antibody, which was then compared with a representative isoform of cytochrome P450. Normal liver biopsy specimens (n = 8) and a spectrum of liver injury biopsy specimens (n = 47) were examined.
RESULTS: Compared with normal liver, increased staining for UGT in remaining hepatocytes was seen in liver damaged by chronic alcohol abuse, but the most intense immunoreactivity was observed in remaining and regenerative hepatocytes in specimens with cirrhosis. Primary biliary cirrhosis showed diffusely increased immunoreactivity. Other nonmalignant groups showed an increased staining relative to chronicity of liver disease. In contrast, in all liver injuries, cytochrome P450 staining was reduced as compared with controls.
CONCLUSIONS: Chronic liver damage results in increased UGT in remaining viable hepatocytes. Mechanisms may operate in liver injury to preserve expression of UGT in functional hepatocytes, and this may explain the preservation of glucuronidation in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729639     DOI: 10.1016/0016-5085(95)90695-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Failure of liver function tests in predicting drug clearance of chemotherapeutic agents in a patient who had recovered from hepatic congestion.

Authors:  Masaharu Tsubokura; Yuji Miura; Tatsuo Itokawa; Naoko Takei; Tadanao Higaki; Toshihiro Amaki; Yasuo Ishida; Makiko Kusama; Shunsuke Ono; Hiroto Narimatsu; Masahiro Kami; Tsunehiko Komatsu
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

2.  Sex hormones differentially regulate isoforms of UDP-glucuronosyltransferase.

Authors:  S I Strasser; S A Smid; M L Mashford; P V Desmond
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

3.  In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Authors:  Els Van Peer; Frank Jacobs; Jan Snoeys; Jos Van Houdt; Ils Pijpers; Christophe Casteleyn; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

4.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 5.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.

Authors:  Anthony T Podany; Kimberly K Scarsi; Michelle M Pham; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2020-09       Impact factor: 6.447

Review 6.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 7.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 8.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

Authors:  Wenhui Zhang; Walter J J Krauwinkel; James Keirns; Robert W Townsend; Kenneth C Lasseter; Lisa Plumb; Takeshi Kadokura; Fumihiko Ushigome; Ronald Smulders
Journal:  Clin Drug Investig       Date:  2013-07       Impact factor: 2.859

10.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.